{"id":390965,"date":"2017-04-20T00:00:00","date_gmt":"2017-04-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcv0005-2017-biopharma-pulmonary-hypertension-current-treatment-physician-insights-us-2017\/"},"modified":"2026-04-30T11:26:46","modified_gmt":"2026-04-30T11:26:46","slug":"cutrcv0005-2017-biopharma-pulmonary-hypertension-current-treatment-physician-insights-us-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcv0005-2017-biopharma-pulmonary-hypertension-current-treatment-physician-insights-us-2017\/","title":{"rendered":"Pulmonary Hypertension | Current Treatment: Physician Insights | US | 2017"},"content":{"rendered":"<p>Pulmonary hypertension (<abbr title=\"pulmonary hypertension\">PH<\/abbr>), particularly pulmonary arterial hypertension (<abbr title=\"pulmonary arterial hypertension\">PAH<\/abbr>), is a rare but life-threatening disorder. Commercial interest in <abbr title=\"pulmonary hypertension\">PH<\/abbr>\/<abbr title=\"pulmonary arterial hypertension\">PAH<\/abbr> has increased recently due to significant advances in the understanding of its etiology and pathophysiology, and the emergence of new therapies to treat it. Despite the relatively small patient population in the major pharmaceutical markets, the <abbr title=\"pulmonary arterial hypertension\">PAH<\/abbr> therapy market is a billion-dollar market that is expected to increase over the coming decade. Our new Current Treatment content provides deep insights into the current treatment of <abbr title=\"pulmonary hypertension\">PH<\/abbr>\/<abbr title=\"pulmonary arterial hypertension\">PAH<\/abbr> in the United States, and the factors behind those treatment decisions.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What impact have the launches of novel therapies such as Uptravi, Orenitram, and Adempas, had on prescribing behavior for <abbr title=\"pulmonary hypertension\">PH<\/abbr> and <abbr title=\"pulmonary arterial hypertension\">PAH<\/abbr>?<\/li>\n<li>What influence has the positive Phase III AMBITION trial, evaluating the upfront dual combination therapy of Letairis and Adcirca, had on the treatment algorithm for <abbr title=\"pulmonary arterial hypertension\">PAH<\/abbr>?<\/li>\n<li>How are specialists utilizing <abbr title=\"pulmonary arterial hypertension\">PAH<\/abbr> therapies for the treatment of <abbr title=\"pulmonary hypertension\">PH<\/abbr><abbr title=\"World Health Organization\">WHO<\/abbr> groups 2-5?<\/li>\n<li>What factors and drug therapy attributes are driving prescribing behavior for the treatment of <abbr title=\"pulmonary arterial hypertension\">PAH<\/abbr>\/<abbr title=\"pulmonary hypertension\">PH<\/abbr>?<\/li>\n<\/ul>\n<p><strong>Scope:<\/strong><\/p>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Methodology:<\/strong> Surveys of 51 cardiologists and 53 pulmonologists\u00a0in the United States, completed in January 2017.<\/p>\n<p><strong>Indication coverage:<\/strong> Pulmonary Hypertension (PH) and Pulmonary Arterial Hypertension (PAH).<\/p>\n<p><strong>Key drugs covered: <\/strong>Uptravi, Orenitram, Adempas, Opsumit, Letairis, Adcirca, Bosentan, Revatio, Tyvaso, Remodulin, Veletri, Flolan.<\/p>\n<p><strong>Key companies mentioned:<\/strong>\u00a0Actelion, Bayer, Gilead, GlaxoSmithKline, United Therapeutics.<\/p>\n","protected":false},"template":"","class_list":["post-390965","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hypertension","biopharma-therapy-areas-pulmonary-hypertension","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390965","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390965\/revisions"}],"predecessor-version":[{"id":394088,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390965\/revisions\/394088"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390965"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}